Positive results from studies of Iprivask for DVT - Marathon Pharma

Marathon Pharma has announced positive results from 2 separate studies of Iprivask/Revasc (Desirudin for Injection) for DVT Prevention in Orthopedic Reconstruction. In Study-1, a Post-Hoc analysis evaluated the safety and efficacy of Iprivask in several high-risk patient subgroups of the pivotal registration multicenter trial comparing desirudin to enoxaparin, in patients undergoing elective total hip replacement (THR) surgery. Results from this analysis demonstrated that patients with various high-risk conditions (e.g. age>65, obesity, cancer, varicose veins, previous VTE) undergoing elective hip replacement, had favorable odds ratio’s for venous thromboembolism (VTE) incidence with desirudin compared with enoxaparin.

In Study-2, an observational study, patients were evaluated for bleeding events and wound outcomes after receiving desirudin administered during the immediate postoperative period after total joint replacement surgery (hip and/or knee), followed by rivaroxaban, for outpatient DVT prophylaxis. This study showed that Iprivask, when initiated post-surgically, resulted in low post-operative complications (i.e. hemoglobin drops, wound discharge, etc) without any thrombotic (DVT) complications. Marathon Pharmaceuticals acquired worldwide rights to Iprivask/Revasc from Canyon Pharmaceuticals in 2013. Data were presented at the International Congress for Joint Reconstruction (ICJR) Transatlantic Meeting.